RNA Therapeutics And Vaccines Market Size, Share and Trends Analysis
The RNA therapeutics and vaccines market reached $10.5 billion in 2023 and is projected to grow at 17.0% CAGR to $42.0 billion by 2032. This report analyzes market trends, segments, and leading players.
Revenue, 2023
$10.5B
Forecast, 2032
$42.0B
CAGR, 2024-2032
17%
Report Coverage
North America
Market Overview
The RNA therapeutics and vaccines market is experiencing rapid growth, driven by technological breakthroughs and the success of mRNA vaccines during the pandemic. This market is projected to reach $42.0 billion by 2032, growing at a CAGR of 17.0% from 2023.
Market Stage
High growth
Adoption Level
Early mainstream
Key Trends
Market Forecast & Data
Base Year (2023)
$12.3B
Forecast (2032)
$42.0B
CAGR (2024-2032)
17%
North America
#1Largest market: United States
Europe
#2Largest market: Germany
Market Dynamics
- Success of mRNA vaccines validating the technology
- Rapid advancements in RNA synthesis and delivery
- Growing pipeline of RNA-based therapeutics
- Increasing R&D investments by major players
Market Segmentation
By Type
- mRNA Therapeutics
- siRNA Therapeutics
- Other RNA Types
By Application
- Infectious Diseases
- Oncology
- Genetic Disorders
- Others
By End User
- Hospitals
- Pharmacies
- Research Institutions
- Others
Regional Analysis
North America
Lead: United StatesNorth America currently leads the market due to high R&D investment, strong presence of key players, and early adoption of advanced therapies.
Europe
Lead: GermanyEurope has a strong biotech sector and is witnessing increasing adoption of RNA-based products, with Germany being the largest contributor.
Asia Pacific
Lead: ChinaAsia Pacific is expected to grow at the fastest rate, driven by expanding healthcare infrastructure, increasing investment in biotechnology, and growing awareness of RNA therapies.
Country-Level Analysis
| Country | Share | Growth |
|---|---|---|
| United States | 40.0% | +18.0% |
| Germany | 25.0% | +16.0% |
| China | 20.0% | +20.0% |
Competitive Landscape
Moderna
USA
Focuses on mRNA vaccines for infectious diseases, cancer, and rare diseases. Has a robust pipeline and commercial success with COVID-19 vaccine.
Pfizer
USA
Partnered with BioNTech for the COVID-19 vaccine. Focuses on RNA-based vaccines for infectious diseases and oncology.
BioNTech
Germany
Specializes in mRNA-based cancer vaccines and infectious disease vaccines. Key partner for Pfizer in the COVID-19 vaccine.
CureVac
Germany
Develops mRNA vaccines for infectious diseases and cancer. Has a focus on next-generation mRNA technology.
GSK
UK
Focuses on RNA-based vaccines for infectious diseases and has a strong pipeline in oncology.
Roche
Switzerland
Investing in RNA therapeutics for oncology and rare diseases, with a focus on siRNA-based products.
Alnylam Pharmaceuticals
USA
Specializes in RNA interference therapeutics, focusing on siRNA-based treatments for rare genetic disorders.
Recent Developments
Initiated phase 3 clinical trial for its personalized cancer vaccine (BNT111).
Announced partnership with a US biotech firm to develop siRNA therapies for cardiovascular diseases.
Expanded its RNA therapeutics pipeline with a new siRNA candidate for neurodegenerative diseases.
Announced phase 3 results for mRNA-4157 (cancer vaccine) in combination with pembrolizumab for melanoma.
Received FDA approval for the mRNA-1647 influenza vaccine.
Secured $200M in funding to advance its next-generation mRNA platform.